Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDGE, Mass., April 19, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,China ,Orlando ,Florida ,United States ,South Korea ,Seongnam ,Kyonggi Do ,Republic Of Korea ,American ,Jimmy Jin ,American Association For Cancer Research ,Drug Administration ,Biotherapeutics Inc ,Bridge Biotherapeutics Inc ,American Association ,Cancer Research ,Investigational New Drug Application ,Epidermal Growth ,Factor Receptor ,Tyrosine Kinase Inhibitor ,With Broad Spectrum Activity ,Molecular Therapeutics ,Tyrosine Kinase ,Phosphatase Inhibitors ,